{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:56:34Z","timestamp":1794412594824,"version":"4.9.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"\n Importance<\/jats:title>\n Neoadjuvant immunotherapy in human papillomavirus (HPV)\u2013negative locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) appears promising, yet its role in nonsurgical treatment for head and neck cancer remains undefined. Neoadjuvant nivolumab plus chemotherapy followed by response-stratified de-escalated chemoradiation therapy (CRT) in HPV-negative LA stage IVa\/b HNSCC may improve treatment efficacy while reducing treatment-related toxic effects.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the deep response rate and tolerability of neoadjuvant nivolumab plus chemotherapy followed by response-stratified CRT in nonvirally mediated stage IVa\/b HNSCC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n In this investigator-initiated phase 2 nonrandomized clinical trial conducted at a single academic center, patients with stage IVa\/b (\n American Joint Committee on Cancer Tumor Classification, 8th edition<\/jats:italic>\n ) HPV-negative LA HNSCC were enrolled between 2019 and 2022. Data were analyzed from February 2023 to January 2024.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The DEPEND trial evaluated neoadjuvant nivolumab plus carboplatin and paclitaxel, followed by response-stratified CRT. Patients with 50% or greater reduction per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 received de-escalated CRT to 66 Gy with elimination of elective nodal volumes; patients with less than 50% reduction received standard CRT to 70 to 75 Gy. Adjuvant nivolumab was administered for 9 cycles.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was deep response rate (DRR; 50% or greater shrinkage per RECIST version 1.1) following neoadjuvant nivolumab plus chemotherapy. Secondary end points included progression-free survival (PFS), overall survival (OS), locoregional control, and distant control. Exploratory end points included acute toxic effects in patients who received response-adapted de-escalated CRT.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 36 included patients, 28 (78%) were male, and the median (range) age was 58.9 (27-77) years. All patients started treatment and were available for analysis. The median (range) follow-up was 20 (13-40) months. The primary end point was met, with a DRR following neoadjuvant nivolumab\/chemotherapy of 53% (95% CI, 35-70). The objective response rate was 86% (95% CI, 71-95). A total of 19 received de-escalated CRT and 16 received standard CRT. PFS and OS at 2 years were 66% (95% CI, 34-76) and 73% (95% CI, 52-86), respectively. The most common treatment-emergent adverse events for de-escalated and standard CRT were mucositis (14 of 19 [74%] and 15 of 16 [94%], respectively), radiation dermatitis (13 of 19 [68%] and 14 of 16 [88%], respectively), and dry mouth (7 of 19 [37%] and 10 of 16 [63%], respectively).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this phase 2 nonrandomized clinical trial, neoadjuvant nivolumab\/chemotherapy led to deep responses in 53% of patients with HPV-negative LA stage IVa\/b HNSCC, and response-adapted de-escalated CRT led to favorable survival with lower acute toxic effects among deep responders.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03944915<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.0081","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:35:12Z","timestamp":1741260912000},"page":"492","source":"Crossref","is-referenced-by-count":37,"title":["Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Ari J.","family":"Rosenberg","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois"},{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Juloori","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Jelinek","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Rush University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Agrawal","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Cursio","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Pathology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Lingen","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Pathology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Izumchenko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois"},{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Katipally","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ginat","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Radiology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pasternak-Wise","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Radiology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Gooi","sequence":"additional","affiliation":[{"name":"Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Blair","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Section of Otolaryngology-Head and Neck Surgery, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois"},{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Haraf","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"},{"name":"Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett E.","family":"Vokes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois"},{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi250002r1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"10318","key":"coi250002r2","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer.","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"coi250002r3","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250002r4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1634\/theoncologist.2020-0303","article-title":"Optimizing treatment de-escalation in head and neck cancer: current and future perspectives.","volume":"26","author":"Rosenberg","year":"2021","journal-title":"Oncologist"},{"key":"coi250002r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105566","article-title":"Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.","volume":"122","author":"Rosenberg","year":"2021","journal-title":"Oral Oncol"},{"issue":"2","key":"coi250002r6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311).","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250002r7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ijrobp.2021.09.012","article-title":"MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma.","volume":"111","author":"Ma","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"coi250002r8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: phase II Trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group.","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10166","key":"coi250002r9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"coi250002r10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002).","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10166","key":"coi250002r11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"issue":"10212","key":"coi250002r12","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"coi250002r13","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score.","volume":"40","author":"Burtness","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10167","key":"coi250002r14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"coi250002r15","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"coi250002r16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study.","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250002r17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"coi250002r18","doi-asserted-by":"publisher","first-page":"S1399","DOI":"10.1016\/j.annonc.2022.08.029","article-title":"LBA5 primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC).","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"coi250002r19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial.","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"issue":"19","key":"coi250002r20","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial.","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi250002r21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"coi250002r22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"coi250002r23","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"coi250002r24","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/annonc\/mdn364","article-title":"Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.","volume":"19","author":"Salama","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"coi250002r25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0360-3016(99)00550-7","article-title":"Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer.","volume":"46","author":"Dawson","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"coi250002r26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial.","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"coi250002r27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/annonc\/mdw051","article-title":"Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.","volume":"27","author":"Villaflor","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"coi250002r28","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/annonc\/mdz171","article-title":"OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann Oncol"},{"issue":"15","key":"coi250002r29","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1200\/JCO.2021.39.15_suppl.6011","article-title":"Nivolumab, nabpaclitaxel, and carboplatin followed by risk\/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.","volume":"39","author":"Rosenberg","year":"2021","journal-title":"J Clin Oncol"},{"key":"coi250002r30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.820587","article-title":"Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma.","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"coi250002r31","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1200\/JCO.1998.16.4.1318","article-title":"Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.","volume":"16","author":"Wendt","year":"1998","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250002r32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"coi250002r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105171","article-title":"A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.","volume":"114","author":"Jelinek","year":"2021","journal-title":"Oral Oncol"},{"issue":"5","key":"coi250002r34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi250002r35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2016.04.030","article-title":"Final results of a randomized phase 2 trial investigating the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation for locoregionally advanced head and neck cancer.","volume":"96","author":"Seiwert","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi250002r36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"coi250002r37","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ijrobp.2022.09.003","article-title":"Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004.","volume":"114","author":"Mell","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi250002r38","doi-asserted-by":"publisher","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial.","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"coi250002r39","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"coi250002r41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma.","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"16","key":"coi250002r42","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1200\/JCO.2023.41.16_suppl.6019","article-title":"Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).","volume":"41","author":"Wong","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi250002r43","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1200\/JCO.2023.41.16_suppl.6008","article-title":"Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): co-primary endpoints and safety results.","volume":"41","author":"Ferrarotto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250002r44","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S1470-2045(20)30327-2","article-title":"Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.","volume":"21","author":"Sun","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"coi250002r45","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-22-1522","article-title":"Randomized phase II study of physiologic MRI-directed adaptive radiation boost in poor prognosis head and neck cancer.","volume":"28","author":"Mierzwa","year":"2022","journal-title":"Clin Cancer Res"},{"key":"coi250002r40","first-page":"101","volume-title":"Immunotherapy for Head and Neck Cancer","author":"Howard","year":"2023"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2830875\/jamaoncology_rosenberg_2025_oi_250002_1747255295.59721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:02:49Z","timestamp":1747306969000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2830875"}},"subtitle":["The DEPEND Phase 2 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.0081","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}